June 17, 2015.
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the early stages, according to GBI Research. This means a significant proportion of therapies are unlikely to reach the market in the near future
The report, Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation, states that 58% of drugs in the pancreatic cancer treatment pipeline are in the discovery or preclinical stages, 17% are in Phase I and 21% are in Phase II, leaving just 4% of products in Phase III of development.
The report adds that while the current global treatment market for pancreatic cancer is comprised of 91% small molecules and 9% biologics, some 41% of the pipeline is formed from biologic therapies.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.